Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel J Beresford

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Expert Opinion on Emerging Drugs|November 13, 2003
Treatments for strokeIsabel J Beresford, Andrew A Parsons, A Jacqueline Hunter
Bioorganic & Medicinal Chemistry Letters|October 29, 2013
The discovery of the benzazepine class of histamine H3 receptor antagonistsDavid M Wilson, James Apps, Nicholas Bailey, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2013
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonistsDavid M Wilson, James Apps, Nicholas Bailey, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2007
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical modelsAndrew D Medhurst, Alan R Atkins, Isabel J Beresford, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Expert Opinion on Emerging Drugs|November 13, 2003
Treatments for strokeIsabel J Beresford, Andrew A Parsons, A Jacqueline Hunter
Bioorganic & Medicinal Chemistry Letters|October 29, 2013
The discovery of the benzazepine class of histamine H3 receptor antagonistsDavid M Wilson, James Apps, Nicholas Bailey, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2013
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonistsDavid M Wilson, James Apps, Nicholas Bailey, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2007
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical modelsAndrew D Medhurst, Alan R Atkins, Isabel J Beresford, et al.
Pageof 1